Effect of Enalapril on the Progression of Chronic Renal Failure
The DOI matches its Crossref record.
Abstract
In order to study the influence of angiotensin converting enzyme (ACE) inhibition on the progression of chronic nephropathy, 70 patients with a median glomerular filtration rate (GFR) of 15 (range, 6 to 54) mL/min/1.73 m2 were randomized in an open study to basic treatment with enalapril or conventional antihypertensive treatment. The patients were followed for at least 2 years or until they needed dialysis. The groups were comparable with respect to age and sex distribution, etiology of renal diseases, initial levels of renal function and arterial blood pressure (BP), and protein intake. The therapeutic goal was a BP of 120 to 140/80 to 90 mm Hg. The GFR, estimated by the plasma clearance of 51Cr-EDTA, was measured every third month, and the individual rate of progression was calculated as the slope of the GFR v time plot. In the enalapril group, the median decline in GFR was -0.20 (range, +0.18 to -7.11) mL/min/1.73 m2/month and in the control group it was -0.31 (+0.01 to -1.97) mL/min/1.73 m2/month (P less than .05). There was no significant difference in blood pressure or plasma lipid levels between the groups. Thus, the progression of moderate to severe chronic nephropathy was slower on a basic treatment with enalapril as compared to conventional antihypertensive therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
Maschio, G., Alberti, D., Janin, G., Locatelli, F., Mann, J. F. E., Motolese, M., Ponticelli, C., Ritz, E., & Zucchelli, P. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604113341502 · Cited by 1,766
Jafar, T. H., Stark, P. C., Schmid, C. H., Landa, M., Maschio, G., de Jong, P. E., de Zeeuw, D., Shahinfar, S., Toto, R., Levey, A. S., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-4-200308190-00006 · Cited by 1,157
Jafar, T. H., Schmid, C. H., Landa, M., Giatras, I., Toto, R., Remuzzi, G., Maschio, G., Brenner, B. M., Kamper, A., Zucchelli, P., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-2-200107170-00007 · Cited by 1,092
Self-citationBakris, G. L., & Weir, M. R. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.5.685 · Cited by 823
Understanding the nature of renal disease progression
Remuzzi, G., Ruggenenti, P., & Benigni, A. (1997) · Kidney International · doi:10.1038/ki.1997.2 · Cited by 649
Chronic kidney disease in children: the global perspective
Warady, B. A., & Chadha, V. (2007) · Pediatric Nephrology · doi:10.1007/s00467-006-0410-1 · Cited by 606
Xie, X., Liu, Y., Perkovic, V., Li, X., Ninomiya, T., Hou, W., Zhao, N., Liu, L., Lv, J., Zhang, H., et al. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.10.011 · Cited by 479
Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease
Jafar, T. H., Stark, P. C., Schmid, C. H., Landa, M., Maschio, G., Marcantoni, C., De Jong, P. E., De Zeeuw, D., Shahinfar, S., Ruggenenti, P., et al. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.0600031131.x · Cited by 377
Long-term Effects of Antihypertensive Agents on Proteinuria and Renal Function
Maki, D. D. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.155.10.1073 · Cited by 273
Reardon, L. C., & Macpherson, D. S. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.1.26 · Cited by 222
Kent, D. M., Jafar, T. H., Hayward, R. A., Tighiouart, H., Landa, M., de Jong, P., de Zeeuw, D., Remuzzi, G., Kamper, A.-L., & Levey, A. S. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006101081 · Cited by 162
Self-citationAngiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial
Maschio, G., Alberti, D., Locatelli, F., Mann, J. F. E., Motolese, M., Ponticelli, C., Ritz, E., Janin, G., & Zucchelli, P. (1999) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199900001-00004 · Cited by 77
Metadata
- Authors
- Kamper, A.-L., Strandgaard, S., & Leyssac, P. P.
- Venue
- American Journal of Hypertension
- Publisher
- Oxford University Press (OUP)
- Published
- 1992-07
- Volume
- 5
- Issue
- 7
- Pages
- 423-430
- ISSN
- 0895-7061 (ISSN-L)
- 1941-7225
- OpenAlex
- W1949417799
- Cited by
- 163
- References
- 0
- FWCI
- 7.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.